FDA Brief

Warning letters Drugs

FDA warning letter to

My Natural Treatment

High riskIssued Feb 22, 2022Posted Feb 23, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned My Natural Treatment over COVID-19 claims for promoted essential oils.

What happened

FDA reviewed the website on January 18, 2022, and FTC reviewed it on February 11, 2022. The site and a Facebook page directed consumers to buy thyme, black seed, eucalyptus, rosemary, and peppermint oils through Amazon Associate links, while the site claimed these oils could prevent or treat COVID-19.

What FDA found

  1. The website’s COVID-19 claims make the promoted essential oils unapproved new drugs.

    FD&C Act §505(a), 21 U.S.C. §355(a)
  2. The same claims make the products misbranded drugs.

    FD&C Act §502, 21 U.S.C. §352
  3. Causing these products to be introduced into interstate commerce is prohibited.

    FD&C Act §§301(a) and (d), 21 U.S.C. §331(a) and (d)
  4. Doing acts to a drug held for sale after interstate shipment that result in misbranding is prohibited.

    FD&C Act §301(k), 21 U.S.C. §331(k)
  5. FTC says the company lacks competent and reliable scientific evidence for disease-prevention or treatment claims.

    FTC Act, 15 U.S.C. §41 et seq.
  6. FTC cites civil penalties for deceptive COVID-19 treatment, cure, prevention, or mitigation claims.

    COVID-19 Consumer Protection Act §1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA requests immediate action to stop sale of unapproved and unauthorized COVID-19 products and asks for an email within 48 hours describing corrective steps; FTC asks for a certification within 48 hours that unsubstantiated claims have ceased.

Who should pay attention

  • affiliate marketers and influencers promoting health products
  • brands whose products are promoted through affiliate links
  • consumer health websites making disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk